Publications
5600 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 6; abstr TPS194); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA)
- Year
- 2022
- Research Committee(s)
- Genitourinary
Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
- Journal / Conference
- BMC Urology Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w.
- Year
- 2022
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID35351104
- PMC
- PMC8966358
- Study Number(s)
- S0000
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials
- Journal / Conference
- JCO Oncology Practice Jun;18(6):e958-e965
- Year
- 2022
- PMID
- PMID35239419
- PMC
- PMC9191302
Survey of US Medical Oncologists’ Practices and Beliefs regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
- Journal / Conference
- JAMA Oncology Apr 1;8(4):1
- Year
- 2022
- Research Committee(s)
- Lung
- PMID
- PMID35142793
- Study Number(s)
- S1400I
Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply
- Journal / Conference
- Cancer Epidemiology Biomarkers & Prevention Mar 10;cebp.EPI-21-1008-E.2021. doi: 10.1158/1055-9965.EPI-21-1008. Online ahead of print
- Year
- 2022
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID35266989
- PMC
- PMC9354799
- Study Number(s)
- S0000, SWOG-9217
Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk
- Journal / Conference
- Cancers (Basel) Apr 14;14(8):1981
- Year
- 2022
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID35454886
- PMC
- PMC9024489
- Study Number(s)
- S0000, SWOG-9217
Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status
- Journal / Conference
- Endocrine-Related Cancer May 9;29(6):335-344
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35324465
- Study Number(s)
- CTSU/C80701
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
- Journal / Conference
- BMC Health Services Research Apr 1;22(1):432
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID35365139
- PMC
- PMC8973954
- Study Number(s)
- S1415CD
Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD
- Journal / Conference
- Clinical Journal of Oncology Nursing Jun 1;26(3):283-292
- Year
- 2022
- Research Committee(s)
- Palliative Care
- PMID
- PMID35604741
- Study Number(s)
- S1820
Altering Intake and Managing Symptoms (AIMS): Feasibility of a Diet Modification Intervention for Post-Treatment Bowel Dysfunction in Rectal Cancer [S1820 Pilot]
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 6543) poster #326; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- LUNGMAP